# Tracy Beth Hoeg

Type: Person

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/tracy-beth-hoeg
Canonical HTML page: https://getbiobrief.com/entity/tracy-beth-hoeg

## Timeline

- **2026-09-08**: HHS fills four senior FDA roles — The Department of Health and Human Services announced permanent directors for the FDA's drug, vaccine and biologics, and tobacco centers, along with a fourth senior position.
- **2026-05**: Hoeg departs CDER — Dr. Tracy Beth Hoeg said she was fired from the Center for Drug Evaluation and Research; Davis began serving in an acting role.
- **2025**: Davis returns to FDA — Michael Davis rejoined the agency as a deputy director after working at a nonprofit pursuing psychedelic drug development.

## Recent coverage (2 stories)

### FDA Drug Chief to Oversee 3 Psychedelic Candidates: Psilocybin, MDMA, LSD
2026-09-09 21:53:23 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

A former psychiatric drug regulator with psychedelic nonprofit experience now leads FDA's drug center as Trump and RFK push faster reviews. Biopharma teams should watch psilocybin, MDMA and LSD programs plus the new vaccines center director.
Full story: https://getbiobrief.com/story/fda-psychedelic-drug-chief-vaccine-director-biotech-impact-2026

### FDA Commissioner Pushes for New Antidepressant Warnings via Controversial Hire
2026-03-04 20:16:14 · Sentiment: Negative · Impact: 7/10 · Sources: 2

FDA Commissioner Marty Makary is reportedly attempting to hire Dr. Tracy Beth Hoeg to lead a new initiative focused on antidepressant safety. The move is tied to a proposed 'bold new warning' for SSRIs and SNRIs, potentially addressing persistent side effects that have long been a point of contention between regulators and the pharmaceutical industry.
Full story: https://getbiobrief.com/story/fda-makary-hoeg-antidepressant-warning-controversy

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.